How much funding has Syneron Bio raised?

Syneron Bio has raised $250.0M in total funding, most recently a Venture Round.

Who are Syneron Bio's investors?

Syneron Bio's investors include ARCH Venture Partners, Lilly Asia Ventures, Tencent, AstraZeneca, AZ-CICC Healthcare Investment Fund, Pfizer Biotech Development Investment Fund.

When was Syneron Bio founded?

Syneron Bio was founded in 2022.

Where is Syneron Bio headquartered?

Syneron Bio is headquartered in Beijing, United States.

What industry is Syneron Bio in?

Syneron Bio operates in Biotech, Healthcare, Artificial Intelligence.

How many employees does Syneron Bio have?

Syneron Bio has 51-200 employees.

Syneron Bio

Next-generation macrocyclic peptide therapeutics powered by the Synova™ platform

Beijing, United States · Founded 2022 · $250.0M raised

Biotech

Healthcare

Artificial Intelligence

Headquarters: Beijing
Employees: 51–200
Founded: 2022
Business Model: B2B

Website: syneronbio.com
Total Funding: $250.0M
Last Round: $150.0M Venture RoundApr 2026
Rounds: 2

About

Syneron Bio is a Beijing-based biotech company dedicated to the development of next-generation macrocyclic peptide therapeutics, leveraging artificial intelligence and drug synthesis technology. The company has completed Series A, A+, and Series B financing rounds totaling approximately $400M, with backers including AstraZeneca. It operates in the intersection of AI and synthetic biology for drug discovery.

Summary

Syneron Bio is a Biotech company based in Beijing, United States, founded in 2022. It has raised $250.0M in total across 2 rounds, most recently a $150.0M Venture Round round in Apr 2026. Investors include ARCH Venture Partners, Lilly Asia Ventures and Tencent.